LENZ THERAPEUTICS, INC. Variable Lease, Cost
LENZ THERAPEUTICS, INC. (LENZ) reported Variable Lease, Cost of $2.20 million for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-27.
Discontinued › Expense Statement › Operating Expenses
us-gaap:VariableLeaseCost · last filed 2024-02-27
- LENZ THERAPEUTICS, INC. variable lease, cost for the quarter ending 2023-12-31 was $400.00K, a 33.33% increase year-over-year.
- LENZ THERAPEUTICS, INC. variable lease, cost for the quarter ending 2023-09-30 was $800.00K, a 166.67% increase year-over-year.
- LENZ THERAPEUTICS, INC. variable lease, cost for the quarter ending 2023-06-30 was $700.00K, a 75.00% increase year-over-year.
- LENZ THERAPEUTICS, INC. variable lease, cost for the quarter ending 2023-03-31 was $400.00K, a 33.33% increase year-over-year.
- LENZ THERAPEUTICS, INC. variable lease, cost for fiscal 2023 was $2.20M, a 69.23% increase from fiscal 2022.
- LENZ THERAPEUTICS, INC. variable lease, cost for fiscal 2022 was $1.30M, a 550.00% increase from fiscal 2021.
- LENZ THERAPEUTICS, INC. variable lease, cost for fiscal 2021 was $200.00K.
| Period end | Variable Lease, Cost 3 month | Variable Lease, Cost 6 month | Variable Lease, Cost 9 month | Variable Lease, Cost 12 month |
|---|---|---|---|---|
| 2023-12-31 | $400.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $1.20M derived: sum of 2 quarters · filed 2024-02-27 | $1.90M derived: sum of 3 quarters · filed 2024-02-27 | $2.20M 10-K · filed 2024-02-27 |
| 2023-09-30 | $800.00K 10-Q · filed 2023-11-13 | $1.50M derived: sum of 2 quarters · filed 2023-11-13 | $1.80M 10-Q · filed 2023-11-13 | $2.20M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-06-30 | $700.00K 10-Q · filed 2023-08-14 | $1.10M 10-Q · filed 2023-08-14 | $1.40M derived: sum of 3 quarters · filed 2024-02-27 | $1.70M derived: sum of 4 quarters · filed 2024-02-27 |
| 2023-03-31 | $400.00K 10-Q · filed 2023-05-11 | $700.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.00M derived: sum of 3 quarters · filed 2024-02-27 | $1.40M derived: sum of 4 quarters · filed 2024-02-27 |
| 2022-12-31 | $300.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | $600.00K derived: sum of 2 quarters · filed 2024-02-27 | $1.00M derived: sum of 3 quarters · filed 2024-02-27 | $1.30M 10-K · filed 2024-02-27 |
| 2022-09-30 | $300.00K 10-Q · filed 2023-11-13 | $700.00K derived: sum of 2 quarters · filed 2023-11-13 | $1.00M 10-Q · filed 2023-11-13 | $1.00M derived: sum of 4 quarters · filed 2023-11-13 |
| 2022-06-30 | $400.00K 10-Q · filed 2023-08-14 | $700.00K 10-Q · filed 2023-08-14 | $700.00K derived: sum of 3 quarters · filed 2023-08-14 | $800.00K derived: sum of 4 quarters · filed 2023-08-14 |
| 2022-03-31 | $300.00K 10-Q · filed 2023-05-11 | $300.00K derived: sum of 2 quarters · filed 2023-05-11 | $400.00K derived: sum of 3 quarters · filed 2023-05-11 | |
| 2021-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-20 | $100.00K derived: sum of 2 quarters · filed 2023-03-20 | $200.00K 10-K · filed 2023-03-20 | |
| 2021-09-30 | $100.00K 10-Q · filed 2021-11-10 | $200.00K 10-Q · filed 2021-11-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Black Diamond Therapeutics, Inc. (BDTX) | United States | $0.109B | -2.48 |
| enGene Therapeutics Inc. (ENGN) | $0.129B | -0.92 | |
| Neumora Therapeutics, Inc. (NMRA) | United States | $0.132B | -1.48 |
| Armata Pharmaceuticals, Inc. (ARMP) | United States | $0.132B | |
| Cardiff Oncology, Inc. (CRDF) | United States | $0.101B | -2.22 |
| Caribou Biosciences, Inc. (CRBU) | United States | $0.134B | -1.79 |
| Tenaya Therapeutics, Inc. (TNYA) | United States | $0.140B | -1.60 |
| COGNITION THERAPEUTICS INC (CGTX) | United States | $0.090B | -6.52 |
| Pelthos Therapeutics Inc. (PTHS) | United States | $0.086B | -1.20 |
| Atara Biotherapeutics, Inc. (ATRA) | United States | $0.086B | -6.48 |